Apixaban versus warfarin in patients with atrial fibrillation.
- Christopher B GrangerJ. Alexander L. Wallentin
- 14 September 2011
Medicine
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial…
- Á. AvezumR. Lopes John H. Alexander
- 23 June 2015
Medicine
There was no evidence of a differential effect of apixaban over warfarin in reducing stroke or systemic embolism, causing less bleeding, and reducing death in patients with and without valvular heart disease.
International variation in and factors associated with hospital readmission after myocardial infarction.
- R. KociolRenato D. Lopes Manesh R Patel
- 4 January 2012
Medicine
Journal of the American Medical Association (JAMA…
There was variation across countries in 30-day readmissions rates after STEMI, with readmission rates higher in the United States than in other countries, and this difference was greatly attenuated after adjustment for length of stay.
Dronedarone in high-risk permanent atrial fibrillation.
- S. ConnollyA. Camm S. Hohnloser
- 14 December 2011
Medicine
Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events and should not be used in such patients.
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
- Jeffrey S HealeyRenato D. Lopes S. Connolly
- 12 November 2023
Medicine
Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.
- R. LopesPatrícia O. Guimarães H. Diener
- 1 June 2017
Medicine
Patients with ICH from the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received ≥1 dose of the study drug are identified.
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
- C. ChristerssonL. Wallentin A. Siegbahn
- 1 September 2014
Medicine
D‐dimer is related to adverse outcomes in arterial and venous thromboembolic diseases and should be considered a potential source of concern for patients with these conditions.
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial
- P. CowperShubin Sheng Daniel B. Mark
- 1 May 2017
Medicine, Economics
Apixaban therapy for ARISTOTLE-eligible patients with atrial fibrillation provides clinical benefits at an incremental cost that represents reasonable value for money judged using US benchmarks for cost-effectiveness, and results were generally consistent when model assumptions were varied.
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial…
- M. RaoS. Halvorsen Christopher B Granger
- 1 December 2015
Medicine
High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism, and strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of strokes in patients with AF.
...
...